Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
12/2010
12/30/2010US20100330201 Therapeutic methods and pharmaceutical compositions for treating warts with tellurium compounds
12/30/2010US20100330198 Aminosugar, glycosaminoglycan, and s-adenosylmethionine composition for the treatment and repair of connective tissue
12/30/2010US20100330197 Oral or enteral composition useful for recovery of physical functions
12/30/2010US20100330184 Injection vehicle for polymer-based formulations
12/30/2010US20100330172 Controlled-release pharmaceutical formulation
12/30/2010US20100330158 Protein-assisted drug delivery system for the targeted administration of active agents
12/30/2010US20100330157 Biomaterial for the controlled delivery of ingredients
12/30/2010US20100330156 Phenazine derivatives and uses thereof
12/30/2010US20100330117 Process for treatment of amyotrophic lateral sclerosis, rheumatoid arthritis, tremors/parkinson's disease, multiple sclerosis, non-viral based cancers, alzheimers's disease, muscular dystrophy, attention deficit disorder, attention deficit hyperactivity disorder, complex regional pain syndrome, diabetes, neuropathic pain, spider arthritis, west nile virus, fibromyalgia, shingles, gout, migraine headaches, senile dementia, post polio syndrome, central virus deafness, asthma, chronic pain of unknown origin and hepatitis c
12/30/2010US20100330110 Therapeutic and diagnostic uses of antibody specificity profiles
12/30/2010US20100330089 Anti-cd20 therapeutic compositions and methods
12/30/2010US20100330077 1-acetic acid-indole derivatives with pgd2 antagonist activity
12/30/2010US20100330064 2-mercaptocyclopentanecarboxylic acid compounds, a process for their preparation and pharmaceutical compositions containing them
12/30/2010US20100330063 Stem-like cells, method for de-differentiating mammalian somatic cells into stem-like cells, and method for differentiating stem-like cells
12/30/2010US20100330052 Use of Mesenchymal Stem Cells for Treating Genetic Diseases and Disorders
12/30/2010US20100330042 Use of Proinsulin for the Preparation of a Neuroprotective Pharmaceutical Composition, Therapeutic Composition Containing it and Applications Thereof
12/30/2010US20100330038 Methods for expressing proteins in axons
12/30/2010US20100329985 Treatment and prevention of inflammatory diseases and autoimmune diseases
12/30/2010US20100329984 Respiratory dispersion for metered dose inhalers
12/30/2010US20100329978 Highly selective sigma receptor ligands
12/29/2010WO2010151852A2 Protease inhibitors, compositions and methods of use
12/29/2010WO2010151815A2 3,9-diazaspiro[5,5]undecane amides and ureas and methods of use thereof
12/29/2010WO2010151755A2 TREATMENT OF INFLAMMATORY DISEASES USING miR-124
12/29/2010WO2010151674A2 Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
12/29/2010WO2010151638A1 Jnk inhibitors for use in treating spinal muscular atrophy
12/29/2010WO2010151611A1 Novel fumarate salts of a histamine h3 receptor antagonist
12/29/2010WO2010151160A1 O-substituted 3-n-heteroaryl-1,3,4-oxadiazolones for medical use
12/29/2010WO2010150995A2 Compositions for treating drug addiction and improving addiction-related behavior
12/29/2010WO2010150899A1 Novel thiophene carboxamide derivative and medicinal use of same
12/29/2010WO2010150865A1 Crystals
12/29/2010WO2010150840A1 N-substituted-cyclic amino derivative
12/29/2010WO2010150281A2 Novel azabicyclohexanes
12/29/2010WO2010150271A1 Process for obtaining purified pterostilbene and methods of use thereof
12/29/2010WO2010150261A1 A method for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition
12/29/2010WO2010149815A1 Olive-oil-based functional oils
12/29/2010WO2010149658A2 Pharmaceutical composition of gamma-butyrobetaine or a pharmaceutically acceptable salt and meldonium or a pharmaceutically acceptable salt
12/29/2010WO2010149363A2 A pharmaceutical composition
12/29/2010WO2010148519A1 Methods and therapies for alleviating pain comprising an ultra low dose of an alpha 2 receptor antagonist
12/29/2010WO2010113183A3 Process for the preparation of 1-[[[3-[2-(dimethylamino)ethyl]-1h-indol-5-yl]methyl]sulfonyl] pyrrolidine and its pharmaceutically acceptable salts
12/29/2010WO2010072327A3 Pharmaceutical composition based on peptide from camel milk
12/29/2010EP2267458A2 Methods, compositions and compound assays for inhibiting amyloid-beta protein production
12/29/2010EP2267445A1 Methods of detecting small intestinal bacterial overgrowth (SIBO) in a human subject
12/29/2010EP2267026A1 Albumin fusion proteins
12/29/2010EP2267010A2 Activatable recombinant neurotoxins
12/29/2010EP2267009A2 Activatable recombinant neurotoxins
12/29/2010EP2267008A2 Activatable recombinant neurotoxins
12/29/2010EP2266990A1 3-PHENYLPYRAZOLOÝ5,1-b¨THIAZOLE COMPOUND
12/29/2010EP2266987A1 Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
12/29/2010EP2266979A1 2-morpholino-4-pyrimidone compounds
12/29/2010EP2266975A1 1-(2-alkyl-2,3-dihydro-benzofuran-4-yl)-pyrrolidin-3-ylamine acyl compounds
12/29/2010EP2266969A2 6-(Pyridinyl)-4-pyrimidone derivatives as tau protein kinase 1 inhibitors
12/29/2010EP2266968A2 Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
12/29/2010EP2266960A2 Aryl-substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles as anticonvulsants
12/29/2010EP2266959A1 8-carboxamido-substituted-2, 6-methano-3-benzazocines and 3-carboxamido-substituted morphanes as opioid receptor binding agents
12/29/2010EP2266719A2 Disposal system for transdermal dosage form
12/29/2010EP2266718A2 Disposal system for transdermal dosage form
12/29/2010EP2266607A2 Immunoconjugates for treating cancer
12/29/2010EP2266600A2 Therapeutic composition with a botulinum neurotoxin
12/29/2010EP2266599A2 Therapeutic composition with a botulinum neurotoxin
12/29/2010EP2266594A1 VEGF for use in the treatment of central nervous system disorders
12/29/2010EP2266570A1 Use of binding partners for 5-HT5 receptors for treating neurodegenerative and neuropsychiatric disorders
12/29/2010EP2266566A2 Nicotinamide derivatives and their use as therapeutic agents
12/29/2010EP2266564A1 Pharmaceutical oral dosage form comprising a combination of an opioid agonist and an opioid antagonist
12/29/2010EP2266558A2 Treatment of neuropathic pain with N-methyl-D-aspartate (NMDA) receptor antagonists
12/29/2010EP2266554A1 Method of treating sleep disorders using eplivanserin
12/29/2010EP2266551A1 Compositions and kits comprising a defined boron compound and methods of their preparation
12/29/2010EP2266550A1 Antagonists of ß-catenin for preventing and/or treating neurodegenerative disorders
12/29/2010EP2266539A2 Methods of treatment using a gastric retained gabapentin dosage
12/29/2010EP2265611A1 Tricyclic derivatives as inhibitors of poly(adp-ribose)polymerase (parp)
12/29/2010EP2265600A1 Pyridinyl amides for the treatment of cns and metabolic disorders
12/29/2010EP2265594A2 Cysteine and cystine bioisosteres to treat schizophrenia and reduce drug cravings
12/29/2010EP2265591A1 Nitrone compounds, process of preparation thereof, and use thereof in medicament manufacture
12/29/2010EP2265589A1 Arylsulfonyl pyrazoline carboxamidine derivatives as 5-ht6 antagonists
12/29/2010EP2265587A1 Modulators of the histamine h3 receptor useful for the treatment of disorders related thereto
12/29/2010EP2265335A1 Indazole derivatives
12/29/2010EP2265291A2 Identification of micro-rnas involved in neuromuscular synapse maintenance and regeneration
12/29/2010EP2265290A1 Oligomer-aryloxy-substituted propanamine conjugates
12/29/2010EP2265288A1 Methods of treating inflammatory pain
12/29/2010EP2265287A1 Methods of treating chronic pain
12/29/2010EP2265269A1 Selective subtype alpha 2 adrenergic agents and methods for use thereof
12/29/2010EP2265174A1 Functionalized magnetic nanoparticles and methods of use thereof
12/29/2010EP2265113A1 Use of ferritin to treat iron deficiency disorders
12/29/2010EP2185512B1 Trans-3-aza-bicyclo[3.1.0]hexane derivatives
12/29/2010EP2142527B1 Pyridine and pyrimidine derivatives as mglur2 antagonists
12/29/2010EP1987066B1 Methods for treating demyelinating diseases
12/29/2010EP1871768B1 Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors
12/29/2010EP1809620B1 Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
12/29/2010EP1805183B1 Novel diazabicyclic aryl derivatives and their medical use
12/29/2010EP1776360B1 3-(heteroaryl-oxy)-2-alkyl-1-aza-bicycloalkyl derivatives as alpha.7-nachr ligands for the treatment of cns diseases.
12/29/2010EP1713810B1 Diazabicyclic aryl derivatives as nicotinic acetylcholine receptor ligands
12/29/2010EP1621202B1 Freeze-dried preparation containing methylcobalamin and process for producing the same
12/29/2010EP1530568B1 INDOLE OR BENZIMIDAZOLE DERIVATIVES FOR MODULATING I&kB KINASE
12/29/2010EP1487802B1 2,3-Diaryl-pyrazolidine derivatives as neurotensin degrading enzyme inhibitors
12/29/2010EP1441727B1 Depot formulations of iloperidone and a star polymer
12/29/2010EP1438052B1 Quinazolin-4-ones as inhibitors of human phosphatidylinositol 3-kinase delta
12/29/2010EP1404312B1 Carbamate compounds for use in the treatment of pain
12/29/2010EP1387673B1 Abuse-resistant controlled-release opioid dosage form
12/29/2010EP1370530B1 Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical
12/29/2010EP1292573B1 Substituted thioacetamides
12/29/2010EP1127069B1 Method of making a monomeric beta-form of a prion protein
1 ... 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 ... 1833